# US 8,278,323 B2 · Opioid antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,323 B2
- Document ID: US8278323B2
- Status: Granted
- Kind: B2
- Application number: 12/463,814
- Filed: 2009-05-11
- Published: 2009-09-03
- Granted: 2012-10-02
- Earliest claimed: 2005-10-27
- Assignees: Adolor Corporation
- Inventors: Roland E. Dolle; Bertrand Le Bourdonnec; Allan James Goodman
- Web page: https://patentgrep.com/patent/US8278323B2

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.

## Claims

### Claim 1

A compound of formula III:
wherein:
R1 is —OH, —ORa, —CH2OH, —C(═O)OR6, —C(═O)NR6R7, or —NR6R7;
R2 and R3 are each independently alkyl or alkenyl;
R4 is H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, alkylaralkyl, or heteroarylalkyl;
X is CH2;
R6 is H, alkyl, cycloalkyl, alkylcycloalkyl, or aralkyl;
R7 is H, alkyl, aralkyl, or aryl;
Ra is a hydroxyl protecting group;
m is 1; and
n is 1
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is —OH or —C(═O)NR6R7.

### Claim 3 (depends on 2)

A compound according to claim 2, having the structure of formula IVa:

### Claim 4 (depends on 3)

A compound according to claim 3, having the structure of formula IVb:

### Claim 5 (depends on 1)

A compound according to claim 1, wherein R2 and R3 are each independently C1-C3alkyl.

### Claim 6 (depends on 5)

A compound according to claim 5, wherein R2 and R3 are each methyl.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein R4 is H, alkyl, cycloalkyl, aryl, or aralkyl.

### Claim 8 (depends on 7)

A compound according to claim 7, wherein R4 is C1-C3alkyl.

### Claim 9 (depends on 8)

A compound according to claim 8, wherein R4 is isopropyl.

### Claim 10 (depends on 1)

A compound according to claim 1, wherein the compound is:
3-(2,3-dimethyl-octahydro-1 H-quinolizin-2-yl)phenol;
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A compound according to claim 1, wherein the compound is:
3-((2R,3R,9□R)-2,3-dimethyl-octahydro-1H-quinolizin-2-yl)phenol; or
3-((2R,3R,9□S)-2,3-dimethyl-octahydro-1H-quinolizin-2-yl)phenol;
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 2)

A pharmaceutical composition, comprising:
a pharmaceutically acceptable carrier; and
an effective amount of a compound according to claim 2.

### Claim 13

A pharmaceutical composition comprising:
a pharmaceutically acceptable carrier;
an effective amount of at least one opioid; and
an effective amount of a compound of Formula IIIa:
wherein:
R1 is —OH, —CH2OH, —C(═O)OR6, —C(═O)NR6R7, or —NR6R7;
R2 and R3 are each independently alkyl or alkenyl;
R4 is H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, alkylaralkyl, or heteroarylalkyl;
X is CH2;
R6 is H, alkyl, cycloalkyl, alkylcycloalkyl, or aralkyl;
R7 is H, alkyl, aralkyl, or aryl;
m is 1; and
n is 1
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

A pharmaceutical composition according to claim 13,
wherein the opioid is alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 15

A method of binding opioid receptors in a patient in need thereof, comprising the step of:
administering to the patient a composition comprising an effective amount of a compound of formula IIIa:
wherein:
R1 is —OH, —CH2OH, —C(═O)OR6, —C(═O)NR6R7, or —NR6R7;
R2 and R3 are each independently alkyl or alkenyl;
R4 is H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, alkylaralkyl, or heteroarylalkyl;
X is CH2;
R6 is H, alkyl, cycloalkyl, alkylcycloalkyl, or aralkyl;
R7 is H, alkyl, aralkyl, or aryl;
m is 1; and
n is 1
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

A method according to claim 15,
wherein the compound binds μ opioid receptors.

### Claim 17 (depends on 16)

A method according to claim 16,
wherein the μ opioid receptors are located in the central nervous system.

### Claim 18 (depends on 16)

A method according to claim 16,
wherein the μ opioid receptors are located peripherally to the central nervous system.

### Claim 19 (depends on 15)

A method according to claim 15,
wherein the compound binds κ opioid receptors.

### Claim 20 (depends on 19)

A method according to claim 19,
wherein the κ opioid receptors are located in the central nervous system.

### Claim 21 (depends on 19)

A method according to claim 19,
wherein the κ opioid receptors are located peripherally to the central nervous system.

### Claim 22 (depends on 15)

A method according to claim 15,
wherein the compound binds □ opioid receptors.

### Claim 23 (depends on 22)

A method according to claim 22,
wherein the □ opioid receptors are located in the central nervous system.

### Claim 24 (depends on 22)

A method according to claim 22,
wherein the □ opioid receptors are located peripherally to the central nervous system.

### Claim 25 (depends on 15)

A method according to claim 15,
wherein the compound exhibits antagonist activity toward the opioid receptors.

### Claim 26

A method of treating ileus, comprising the step of:
administering to a patient in need thereof, a composition comprising an effective amount of a compound of formula IIIa:
wherein:
R1 is —OH, —CH2OH, —C(═O)OR6, —C(═O)NR6R7, or —NR6R7;
R2 and R3 are each independently alkyl or alkenyl;
R4 is H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, alkylaralkyl, or heteroarylalkyl;
X is CH2;
R6 is H, alkyl, cycloalkyl, alkylcycloalkyl, or aralkyl;
R7 is H, alkyl, aralkyl, or aryl;
m is 1; and
n is 1
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

A method according to claim 26,
wherein the ileus is post-operative ileus.

### Claim 28

A method of treating pain, comprising the step of:
administering to a patient in need thereof, a composition comprising:
an effective amount of an opioid; and
an effective amount of a compound of formula IIIa:
wherein
R1 is —OH, —CH2OH, —C(═O)OR6, —C(═O)NR6R7, or —NR6R7;
R2 and R3 are each independently alkyl or alkenyl;
R4 is H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, alkylaralkyl, or heteroarylalkyl;
X is CH2;
R6 is H, alkyl, cycloalkyl, alkylcycloalkyl, or aralkyl;
R7 is H, alkyl, aralkyl, or aryl;
m is 1; and
n is 1
or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 28)

A method according to claim 28,
wherein the opioid is alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 30 (depends on 1)

A compound according to claim 1, wherein R4 is aryl.

### Claim 31 (depends on 30)

A compound according to claim 30, wherein R4 is C6aryl.

### Claim 32 (depends on 31)

A compound according to claim 31, wherein R4 is phenyl.
